作者
Georg Petzold,Pablo Gaínza,Stefano Annunziato,Ilaria Lamberto,Peter Trenh,L. L. McAllister,Bradley Demarco,Laura Schwander,R.D. Bunker,Mary Zlotosch,Rohitha Sriramaratnam,Samuel Gilberto,Gerasimos Langousis,Etienne J. Donckèle,Chao Quan,Vaïk Strande,Gian Marco De Donatis,Shanique Alabi,Janneke C. Alers,Michelle Matysik,Camille Staehly,A. Jay DuBois,Arnaud Osmont,Mackenzie Garskovas,David Lyon,L. Wiedmer,Vladas Oleinikovas,Raphael Lieberherr,Nooreen Rubin,Daniel T. Lam,Nina Ilic Widlund,Andreas Ritzén,Ramon Miguel Caceres,Dominico Vigil,Jennifer J. Tsai,Owen B. Wallace,Marisa O. Peluso,Amine Sadok,Alison M. Paterson,Vladislav Zarayskiy,Bernhard Fasching,Débora Bonenfant,Markus Warmuth,John Castle,Sharon A. Townson
摘要
Abstract The CRL4 CRBN ubiquitin ligase is leveraged by molecular glue degraders, small molecules that reprogram ligase specificity to induce degradation of clinically relevant neosubstrate proteins. Known CRBN neosubstrates share a generalizable β-hairpin G-loop recognition motif, yet systematic exploration of the CRBN target landscape is still pending. Through computational mining of the human proteome using structure-based approaches, we predict over 1,400 CRBN-compatible β-hairpin G-loop proteins across diverse target classes, identify novel mechanisms of neosubstrate recognition through structurally differentiated helical motifs and molecular surface mimicry, and validate 22 representative neosubstrates with clinical implications. This work broadens the CRBN target space, redefines rules for neosubstrate recognition and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.